Sage wins Very best Feature Set and Usability awards from TrustRadius for Sage Intacct cloud financial administration process

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a medical-stage biotechnology business concentrated on the advancement of novel therapies with the opportunity to make improvements to the life of clients with immune-mediated diseases, today announced the pricing of an underwritten general public presenting of 6,842,106 shares of its prevalent stock at a public providing cost of $9.50 for every share. The gross proceeds from the giving, just before deducting underwriting special discounts and commissions and believed providing fees payable by Aldeyra, are expected to be approximately $65. million. In addition, Aldeyra granted the underwriters a 30-day selection to invest in up to 1,026,315 extra shares of common stock at the community featuring selling price, much less the underwriting discounts and commissions. All of the shares in the supplying are staying marketed by Aldeyra. Aldeyra anticipates utilizing the web proceeds from the supplying for the continued progress of Aldeyra’s guide compound, reproxalap, and its other solution candidates, as perfectly as for working cash, and other general company functions. The presenting is anticipated to shut on or about January 19, 2021, subject matter to customary closing problems.

Jefferies LLC and SVB Leerink LLC are acting as joint reserve-working supervisors for the supplying. BTIG LLC and Oppenheimer & Co. Inc. are performing as co-direct supervisors for the giving.

The shares of widespread inventory explained earlier mentioned are staying supplied by Aldeyra pursuant to a shelf registration statement on Sort S-3 earlier filed with the Securities and Exchange Commission (SEC) and declared productive by the SEC on July 27, 2018. A preliminary prospectus health supplement relating to and describing the terms of the presenting has been submitted with the SEC and is readily available on the SECs net internet site at Copies of the closing prospectus complement (when available) and accompanying prospectus relating to these securities may well also be obtained by sending a request to: Jefferies LLC, Focus: Fairness Syndicate Prospectus Office, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at 877-821-7388 or by email at [email protected], or from SVB Leerink LLC, Notice: Syndicate Department, One Federal Street, 37th Ground, Boston, Massachusetts 02110, by telephone at 1-800-808-7525, ext. 6132, or by electronic mail at [email protected].

This push launch does not constitute an offer you to provide or the solicitation of an present to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be illegal prior to the registration or qualification underneath the securities laws of any these condition or other jurisdictions.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a medical-stage biotechnology corporation focused on the enhancement of novel therapies with the probable to strengthen the life of patients with immune-mediated conditions. Two of the companys guide investigational compounds, reproxalap and ADX-629, concentrate on RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory illness and final result in cytokine release by means of activation of a broad array of inflammatory factors, which include NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is staying evaluated in Phase 3 scientific trials in individuals with dry eye disorder and allergic conjunctivitis. The companys medical pipeline also features ADX-2191, a dihydrofolate reductase inhibitor in Period 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.

Secure Harbor Statement

This launch incorporates forward-searching statements in the which means of Section 21E of the Securities Trade Act of 1934, as amended, like but not restricted to statements regarding the closing of the community featuring and the expected use of the proceeds thereof. These ahead-searching statements are issue to a quantity of risks, which include the pleasure of customary closing problems associated to the proposed public offering and the threat factors established forth from time to time in Aldeyras SEC filings, such as but not confined to the risks that are described in the Possibility Elements and Managements Dialogue and Assessment of Financial Affliction and Outcomes of Functions sections of Aldeyras Once-a-year Report on Form 10-K for the yr ended December 31, 2019 and Aldeyras Quarterly Report on Sort 10-Q for the quarter finished September 30, 2020 which are on file with the SEC and obtainable on the SEC’s site at In addition to the dangers explained over and in Aldeyras other filings with the SEC, other mysterious or unpredictable elements also could influence Aldeyras outcomes. No forward-searching statements can be certain and genuine outcomes could differ materially from these kinds of statements. The info in this launch is offered only as of the day of this launch, and Aldeyra undertakes no obligation to update any forward-on the lookout statements contained in this release on account of new facts, foreseeable future situations, or usually, apart from as expected by legislation.

Corporate Speak to:

David McMullin

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

[email protected]

Investor & Media Speak to:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

[email protected]